Advertisement

Clinical and Translational Oncology

, Volume 17, Issue 2, pp 103–112 | Cite as

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  • E. FelipEmail author
  • Á. Concha
  • J. de Castro
  • J. Gómez-Román
  • P. Garrido
  • J. Ramírez
  • D. Isla
  • J. Sanz
  • L. Paz-Ares
  • F. López-Ríos
Educational series – Red Series New Trends in Clinical Oncology

Abstract

In 2011, the Spanish Society of Medical Oncology and the Spanish Society of Pathology started a joint project to establish recommendations on biomarker testing in patients with advanced non-small-cell lung cancer based on the current evidence. Most of these recommendations are still valid, but new evidence requires some aspects to be updated. Specifically, the recommendation about which biomarkers to test in which patients is being amended, and the best way to manage tumour samples and minimum requirements for biomarker test material are defined. Suitable techniques for testing for epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement are also reviewed, and a consensus is reached on which situations warrant re-biopsy.

Keywords

ALK Biomarkers EGFR Lung cancer 

Notes

Acknowledgments

The authors are grateful for the editorial assistance of Ana Martín of HealthCo (Madrid, Spain) in the production of this manuscript. F. López-Ríos thanks B. Angulo and E. Conde for their contribution to lung carcinoma targeted therapies. SEOM and SEAP are grateful for financial support for this project in the form of unrestricted grants from AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Pfizer and Roche.

Conflict of interest

The authors declare that, when writing and revising the text, they did not know the names of the pharmaceutical companies that provided financial support for this project, so this support has not influenced the content of this article.

References

  1. 1.
    Garrido P, de Castro J, Concha A, Felip E, Isla D, Lopez-Rios F, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol. 2012;14:338–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67.PubMedCrossRefGoogle Scholar
  3. 3.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Camps C, Felip E, Garcia-Campelo R, Trigo JM, Garrido P. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clin Transl Oncol. 2013;15:977–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S et al. 2nd ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–90. doi: 10.1093/annonc/mdu145.
  8. 8.
    Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Fan L, Feng Y, Wan H, Shi G, Niu W (2014) Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. Available at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0100866. Accessed July 2014. PLoS One.
  10. 10.
    Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba, II et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006.Google Scholar
  11. 11.
    Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Mok T, Kim D-W, Wu Y-L, Solomon BJ, Nakagawa K, Mekhail T et al (2014) (First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 32: 5s (suppl; abstr 8002).Google Scholar
  13. 13.
    Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–97.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Kim D-W, Mehra R, Tan DS-W, Felip E, Chow LQM, Camidge DR, et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. ASCO Meet Abstr. 2014;32:8003.Google Scholar
  15. 15.
    Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol. 2012;36:895–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Conde E, Angulo B, Izquierdo E, Paz-Ares L, Belda-Iniesta C, Hidalgo M, et al. Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clin Transl Oncol. 2013;15:503–8.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lopez-Rios F, Conde E, Angulo B, Martinez R, McGready C, O’Hara G, et al. A prospective protocol for simultaneous genomic testing in patients with non-small cell lung cancer. J Thorac Oncol. 2013;8:S1074.Google Scholar
  18. 18.
    EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. NICE diagnostics guidance 9. Available at http://guidance.nice.org.uk/nicemedia/live/14251/64893/64893.pdf. Accessed May 2014.
  19. 19.
    Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828–60.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220–9.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012;18:1790–7.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Hutarew G, Hauser-Kronberger C, Strasser F, Llenos IC, Dietze O. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology. 2014;65(3):398–407. doi: 10.1111/his.12399.
  23. 23.
    FDA clears BioView Duet™ system for automated ALK FISH scanning of lung cancer tissue specimens. Available at http://www.bioview.co.il/htmls/page_70.aspx?c0=12677&bsp=12624. Accessed June 2014.
  24. 24.
    Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Baron AE, et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer. 2013;119:3968–75.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Salido M, Pijuan L, Martinez-Aviles L, Galvan AB, Canadas I, Rovira A, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2011;6:21–7.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461:245–57.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Selinger CI, Rogers TM, Russell PA, O’Toole S, Yip P, Wright GM, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014;9:631–8.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Zwaenepoel K, Van Dongen A, Lambin S, Weyn C, Pauwels P. Detection of ALK expression in NSCLC with ALK-gene rearrangements: comparison of multiple IHC methods. Histopathology. 2014. doi: 10.1111/his.12414.
  30. 30.
    Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012;25:1462–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810–27.PubMedCrossRefGoogle Scholar
  32. 32.
    Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17:1169–80.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013;119:4325–32.PubMedCrossRefGoogle Scholar
  34. 34.
    Janne PA, Ramalingam SS, Yang JC-H, Ahn M-J, Kim D-W, Kim S-W, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2014;32:8009.Google Scholar
  35. 35.
    Sequist LV, Soria J-C, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). ASCO Meet Abstr. 2014;32:8010.Google Scholar
  36. 36.
    Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71:6051–60.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, et al. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res. 2014;20:2264–75.PubMedCrossRefGoogle Scholar
  38. 38.
    Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013;31:1097–104.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol. 2013;31:1112–21.PubMedCrossRefGoogle Scholar
  40. 40.
    Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863–70.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R et al. Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. N Engl J Med. 2014 [Epub ahead of print].Google Scholar
  42. 42.
    Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046–51.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–4.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910–8.PubMedCrossRefGoogle Scholar
  45. 45.
    The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543–50.Google Scholar
  46. 46.
    Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014;16:229–43.PubMedCrossRefGoogle Scholar
  47. 47.
    Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013;137:668–84.PubMedCrossRefGoogle Scholar
  48. 48.
    Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86.PubMedCrossRefGoogle Scholar
  49. 49.
    Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev. 2014;40:648–55.PubMedCrossRefGoogle Scholar
  50. 50.
    O’Flaherty JD, Gray S, Richard D, Fennell D, O’Leary JJ, Blackhall FH, et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer. 2012;76:19–25.PubMedCrossRefGoogle Scholar
  51. 51.
    Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366–77.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res. 2011;17:7808–15.PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2014

Authors and Affiliations

  • E. Felip
    • 1
    Email author
  • Á. Concha
    • 2
  • J. de Castro
    • 3
  • J. Gómez-Román
    • 4
  • P. Garrido
    • 5
  • J. Ramírez
    • 6
  • D. Isla
    • 7
  • J. Sanz
    • 8
  • L. Paz-Ares
    • 9
  • F. López-Ríos
    • 10
  1. 1.Department of Medical Oncology, Oncology ServiceHospital Universitari Vall d’HebronBarcelonaSpain
  2. 2.Department of PathologyComplejo Hospitalario Universitario A CoruñaA CoruñaSpain
  3. 3.Department of Medical OncologyHospital Universitario La PazMadridSpain
  4. 4.Department of Pathology, Hospital Universitario Marqués de ValdecillaUniversidad de Cantabria, IDIVALSantanderSpain
  5. 5.Department of Medical OncologyHospital Universitario Ramón y CajalMadridSpain
  6. 6.Department of Pathology, Hospital Clinic, IDIBAPS, CIBERESUniversidad de BarcelonaBarcelonaSpain
  7. 7.Department of Medical OncologyHospital Clínico Lozano BlesaZaragozaSpain
  8. 8.Department of Pathology, Facultad de MedicinaUniversidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)MadridSpain
  9. 9.Department of Medical OncologyInstituto de Biomedicina de Sevilla, IBIS (Hospital Universitario Virgen del Rocío, Universidad de Sevilla, CSIC)SevilleSpain
  10. 10.Laboratorio de Dianas Terapéuticas, Department of PathologyHospital Universitario SanchinarroMadridSpain

Personalised recommendations